ZLAB - Zai Lab Limited

NasdaqGM - NasdaqGM Real-time price. Currency in USD

Zai Lab Limited

Jinchuang Plaza
Building 1, Fourth Floor 4560 Jinke Road Pudong
Shanghai 201210
86 21 6163 2588

Full-time employees2,036

Key executives

NameTitlePayExercisedYear born
Dr. Ying Du Ph.D.Founder, Chairperson & CEO1.67MN/A1966
Mr. Joshua L. SmileyPres & COO647.11kN/A1970
Dr. Rafael G. Amado M.D.Pres and Head of Global Oncology R&D477kN/A1964
Mr. Ki Chul ChoChief Financial Officer748.24kN/A1978
Dr. Harald Reinhart M.D.Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases923.33k68.6k1952
Dr. Peter Huang Ph.D.Chief Scientific OfficerN/AN/AN/A
Mr. Frazor Titus Edmondson IIIChief Legal Officer & Corp. Sec.N/AN/A1966
Ms. Ann E. Beasley J.D.Chief Compliance OfficerN/AN/AN/A
Dr. Ning Xu M.D.Exec. VP & Head of Clinical OperationsN/AN/A1965
Dr. Jonathan J. Wang MBA, Ph.D.Chief Bus. OfficerN/AN/A1982
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Corporate governance

Zai Lab Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.